168 words) 20 Recent advances in machine learning have allowed identification of molecular and 21 cellular factors that underly successful antibody responses to influenza vaccines.
Results of these studies have revealed the high level of complexity necessary to 23 establish influenza immunity, and many different cellular and molecular components 24 involved. However, identified correlates of protection fail to account for the majority of 25 vaccinated cases across ages, cohorts, and influenza seasons. Major challenges arise 26 from small sample sizes and from analysis of only one aspect of the biology such by 27 using transcriptome data. The objective of the current study is to create a unified 28 database, entitled FluPRINT, to enable a large-scale study exploring novel cellular and 29 molecular underpinnings of successful immunity to influenza vaccines. Over 3,000 30 parameters were considered, including serological responses to influenza strains, 31 serum cytokines, cell subset phenotypes, and cytokine stimulations. FluPRINT, thus 32 facilitates application of machine learning algorithms for data mining. The data are 33 publicly available and represent a resource to uncover new markers and mechanisms 34 that drive successful influenza vaccination. 35
Background and Summary (394 words) 36 Influenza virus has a devastating societal impact, causing up to 650,000 deaths 37 every year worldwide 1 . Vaccination can prevent influenza-like illnesses, and thus lower 38 the risk of the virus outbreak. However, currently available vaccines do not always 39 provide protection, even among otherwise-healthy people, leading to serious 40 pandemics. Application of computational biology and machine learning to clinical 41 datasets holds promise for identifying immune cell populations and genes that mediate 42 stronger antibody responses to influenza vaccines 2-9 . Lack of pre-existing influenza 43 immunity, especially T cells, has been identified as one of the major predispositions for 44 failure to generate effective response to vaccination 10-12 . However, exact phenotypes 45 of CD4 + and CD8 + T cells, which are important for protective influenza immunity in 46 general and to vaccination with live attenuated influenza vaccine (LAIV) in specific, 47 remain elusive. Identified correlates of protection, moreover, are not consistent 48 between cohorts and study years. Some of the identified challenges leading to such 49 discrepancy are small sample sizes and analysis of only one aspect of the biology, 50 such as molecular correlates of protection by using transcriptome data 13 . Additionally, 51 comparison of the results of different predictive models is hampered by the lack of a 52 consensus regarding what defines the outcome of vaccination, i.e. high vs. low 53 responders. For these reasons, it is necessary to generate a unified dataset that 54 includes multiple measurements across age, gender, and racially diverse populations. 55 3 Specifically, it is of the utmost importance to include single-cell analysis at the protein 56 level, such as mass cytometry combined with multiple high-dimensional biological 57 measurements, since these have power to reveal heterogeneity of the immune 58 system [14] [15] [16] [17] [18] . 59
To accomplish that goal, we generated FluPRINT, a dataset consisting of 14 60
data types in standardized tables on blood and serum samples taken from 747 61 individuals undergoing influenza vaccination (Fig. 1) . The FluPRINT dataset contains 62 information on more than 3,000 parameters measured using mass cytometry (CyTOF), 63 flow cytometry, phosphorylation-specific cytometry (phospho-flow), multiplex ELISA 64 were stratified into high and low responders, depending on their HAI antibody titers 99 measured before and after vaccination, as described below. Figure 2 shows 100 demographic information for the FluPRINT study population, including gender, 101 ethnicity, cytomegalovirus (CMV) status, and age stratified by the outcome to 102 vaccination. Out of 364 individuals with measured HAI responses, 111 were identified 103 as high responders and 253 as low responders. Overall, no major differences in the 104 gender, ethnicity distribution, or CMV status ( Fig. 2a ) or age ( Fig. 2b) were observed 105 between high and low responders. 106
Assays performed. All data used were analysed and processed at the HIMC, 107
as previously described 22 . Protocols for all assays performed such as 108 immunophenotyping and determination of signalling responses to stimulation using 109 flow or mass cytometry, HAI titer determination and analysis of cytokines/chemokines 110 in samples using Luminex assay are available online 19 . Immunophenotyping using 111 mass cytometry was published in Leipold and Maecker 23 . Previous studies describe: 112 phospho-flow assay using flow cytometry (for studies SLVP015, SLVP018 and 113 SLVP021 from 2007 to 2012) 4,21 , mass cytometry (for studies SLVP015, SLVP018 and 114 SLVP021 in 2013) 24 and Luminex assay 4,21 . The HAI assay was performed on sera 115 from day 0 and day 28 using a well-established method 25 as previously described 3, 4 . 116
The distribution of assays performed across clinical studies and years is illustrated in 117 Table 2 . Overall, SLVP015 was the longest study, running from 2007 to 2014, spanning 118 135 unique individuals, while the majority of samples (256) came from the SLVP018 119 study ( Fig. 1) . 120
Automated importer and data harmonization. After collecting the data, a 121 custom PHP script was generated to parse each of the 177 CSV files and to import 122 data into the MySQL database. The source code for the script is available online at 123 https://github.com/LogIN-/fluprint. The script optimizes the data harmonization process 124 essential for combining data from different studies. Control and nonsense data were 125 not imported, such as "CXCR3-FMO CD8+ T cells", "nonNK-nonB-nonT-126 nonmonocyte-nonbasophils", "viable", etc. To standardize data, the original CSV 127 entries were cleaned into the MySQL database readable format (e.g. quotes and 128 parenthesis replaced with underscores, "+" with text "positive", etc.). Additionally, 129 classifications for ethnicity, vaccine names and age were resolved into standard forms. 130
For example, "Fluzone single-dose syringe" and "Fluzone single-dose syringe 2009-131 2010" were mapped to "Fluzone". During data merging, we replaced text strings with 132 binary values. For example, for the variable of gender, female and male were replaced 133 with zero and one. To be able to distinguish between visits in consecutive years, an 134 internal visit identification was calculated. For the original internal visit data, each visit 135
in one year was labelled as V1 for day zero and V2 for day seven. However, if the same 136 individual came in the consecutive year, day zero visit would again be labelled V1, and 137 day seven as visit V2, causing repetition of values. To avoid such repetitions in the 138 database, we also generated a unique visit ID. Therefore, for the above example, first 139 visit in the first year would be labelled V1 for day zero and V2 for day seven, but for the 140 next year visits would be labelled as V3 for day zero and V4 for day seven. To 141 distinguish between Luminex assays, the prefix L50 was given to each analyte 142 analysed with the 51/52-plex Luminex kit. Finally, we imputed new values and 143 calculated the vaccine outcome parameter using HAI antibody titers. High responders 144
were determined as individuals that have HAI antibody titer for all vaccine strains above 145 Table 3 . 183
Technical Validation

184
The FluPRINT dataset was validated on two levels: (1) upon insertion and (2) 185 after the data was inserted into the database. To validate data on insertion, we created 186 loggers to monitor import of the CSV files into the database. This ensured easier and 187 more effective troubleshooting of potential problems and contributed to the monitoring 188 of the import process. Two different sets were used: (1) informative and (2) error 189 loggers. Informative loggers provided information about which processing step has 190 started or finished and how many samples have been processed in that particular step. 191
This allowed us to monitor that correct number of samples was processed. Error 192 loggers provided exact identification and name of the data which could not be imported 193 into the database, usually caused by missing or incorrect user input, such as "…assay 194 is missing. Skipping …'$row'". This facilitated the process to identify erroneous data, 195 which were then manually reviewed, corrected, and updated. Application of machine learning algorithms to clinical datasets can reveal biomarkers 206 for different diseases, therapies 26 , including vaccinations 2,3,6 . The data from the 207
FluPRINT study can be used to identify cellular and molecular baseline biomarkers that 208 govern successful antibody response to influenza vaccines (inactivated influenza 209 vaccine, IIV and LAIV) across different influenza seasons and a broad age population. 210
Since FluPRINT dataset is provided as a database, this facilitates further analysis. 211
Queries can be easily performed to obtain a single CSV file. For example, researchers 212 interested in understanding which immune cells and chemokines can differentiate 213 between high and low responders that received inactivated influenza vaccine could 214 search the FluPRINT database. In the database, they can find all donors for which flow 215 cytometry or mass cytometry were performed together with Luminex assays, for which 216 donors the HAI response was measured, and all the donors who received inactivated 217 influenza vaccine. The resulting CSV file can then easily be used for downstream 218
analysis. 219
Major advantages of this dataset are the mapping of the vaccine outcome, 220 classifying individuals as high or low responders, standardization of the data from 221 different clinical studies, and from different assays. This data harmonization process 222 allows for direct comparison of immune cell frequency, phenotype, and functionality 223 and quantity of chemokines and cytokines shared between individuals before or after 224 influenza vaccinations. By releasing the FluPRINT database and the source code, we 225 provide users with the ability to continue building upon this resource and to update the 226 database with their data and other databases. 227
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